News
Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...
While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early
